RS
MRVI icon

R Squared’s Maravai LifeSciences MRVI Stock Holding History

R Squared’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Sell
19,822
-7,572
-28% -$32.7K 0.06% 387
2026
Q1 		$77.5K Buy
27,394
+11,827
+76% +$40.1K 0.04% 390
2025
Q4 		$50.6K Buy
+15,567
New +$52.4K 0.02% 459

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

R Squared's MRVI Position: Q2 2026 in Review

R Squared reduced its Maravai LifeSciences (MRVI) stake by 28% in Q2 2026, selling an estimated $32.7K and leaving 19,822 shares worth $124K. The position accounts for 0.06% of the portfolio, ranked #387.

R Squared first reported a position in MRVI in Q4 2025 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • R Squared held 19,822 shares of Maravai LifeSciences worth $124K as of Q2 2026.
  • R Squared sold 7,572 Maravai LifeSciences shares in Q2 2026, an estimated $32.7K.
  • Maravai LifeSciences made up 0.06% of R Squared's portfolio in Q2 2026, its #387 holding.
  • R Squared first reported a position in Maravai LifeSciences in Q4 2025 and has held it in 3 quarters since.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.